XBIO joined OTCQB a year ago having completed a re
Post# of 74
Previously Xenetic was listed on AIM (LSE) and traded at the equivalent of 20-50 cents for a number of years.
The Board hoped that by moving the company/listing to the US that a truer value of the many compounds under development would be realised, along with a greater source of funding to continue operations.
Just under a year ago funds were raised at just under $1, and the SP for much of the year reflected that. The company is carrying out further fundraising at present, which I believe has depressed the SP to the current level - or rather the uncertainty associated with it has. It could well be an excellent time to invest here while the SP is at the current low level.
The board are hoping to list on NASDAQ as soon as possible. The delay could well be due to the lack of liquidity in the past months.